Loading institutional data...
Loading institutional data...
Held by 262 of 5,944 reporting institutions (93th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $152.91 today, the market must believe free cash flow compounds 20.4%/yr for a decade (off $100M normalized FCF).
The market's 20.4% is more optimistic than its 9-yr track record.
2-stage DCF · 0.02B shares · net debt $1.3B
mean 318.8% · volatility σ 981% · implied rate exceeded in 3/8 yrs
Central path = implied 20.4%/yr growth; shaded band = ±1σ (981%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.23B 100.0% | $2.38B 100.0% | $2.26B 100.0% | $2.28B 100.0% | $1.32B 100.0% | $1.27B 100.0% | $1.27B 100.0% | $1.40B 100.0% | $1.29B 100.0% | $379.4M 100.0% |
| Cost of Revenue | $1.41B 63.2% | $1.56B 65.4% | $1.52B 67.2% | $1.58B 69.4% | $824.8M 62.7% | $809.5M 63.7% | $794.3M 62.7% | $830.0M 59.3% | $866.5M 67.0% | $178.0M 46.9% |
| Cost of Products | — | — | — | — | — | — | — | — | $866.5M 67.0% | $178.0M 46.9% |
| Gross Profit | $822.0M 36.8% | $824.8M 34.6% | $739.9M 32.8% | $697.8M 30.6% | $491.5M 37.3% | $461.5M 36.3% | $471.9M 37.3% | $570.0M 40.7% | $426.1M 33.0% | $201.4M 53.1% |
| Research & Development | $87.5M 3.9% | $88.6M 3.7% | $85.3M 3.8% | $93.0M 4.1% | $47.5M 3.6% | $42.9M 3.4% | $48.6M 3.8% | $52.9M 3.8% | $51.3M 4.0% | $13.0M 3.4% |
| Selling, General & Admin | $625.2M 28.0% | $638.8M 26.8% | $606.7M 26.9% | $608.3M 26.7% | $302.6M 23.0% | $284.0M 22.3% | $277.0M 21.9% | $320.0M 22.9% | $302.2M 23.4% | $89.4M 23.6% |
| Total Operating Expenses | $779.2M 34.9% | $781.8M 32.8% | $717.0M 31.7% | $740.7M 32.5% | $368.2M 28.0% | $363.3M 28.6% | $364.5M 28.8% | $540.3M 38.6% | $439.4M 34.0% | $118.5M 31.2% |
| Operating Income | $42.8M 1.9% | $43.0M 1.8% | $22.8M 1.0% | -$42.9M -1.9% | $123.2M 9.4% | $98.2M 7.7% | $107.4M 8.5% | $29.8M 2.1% | -$13.3M -1.0% | $82.9M 21.9% |
| Interest Expense | $93.3M 4.2% | $106.5M 4.5% | $102.7M 4.5% | $70.8M 3.1% | $858K 0.1% | $1.8M 0.1% | $549K 0.0% | $709K 0.1% | $2.0M 0.2% | $118K 0.0% |
| Interest & Investment Income | $10.3M 0.5% | $10.8M 0.5% | $7.5M 0.3% | $4.4M 0.2% | $2.8M 0.2% | $3.7M 0.3% | — | — | — | — |
| Other Income (Expense), net | -$232K -0.0% | -$13.2M -0.6% | -$5.9M -0.3% | -$5.1M -0.2% | -$2.0M -0.2% | -$2.6M -0.2% | $7.9M 0.6% | -$6.7M -0.5% | -$4.3M -0.3% | $885K 0.2% |
| Pretax Income | $4.4M 0.2% | -$66.0M -2.8% | -$78.3M -3.5% | — | — | $97.5M 7.7% | $114.7M 9.1% | $22.4M 1.6% | $51.3M 4.0% | $85.2M 22.4% |
| Income Tax Expense | $2.4M 0.1% | $51.7M 2.2% | -$48.6M -2.2% | -$40.1M -1.8% | $20.1M 1.5% | $10.6M 0.8% | $13.7M 1.1% | -$6.4M -0.5% | -$17.4M -1.3% | $22.1M 5.8% |
| Net Income | $732K 0.0% | -$117.7M -4.9% | -$29.7M -1.3% | -$74.3M -3.3% | $103.1M 7.8% | $86.9M 6.8% | $101.0M 8.0% | $28.8M 2.1% | $68.6M 5.3% | $63.1M 16.6% |
| Per Share | ||||||||||
| EPS (Basic) | $0.03 | $-4.83 | $-1.23 | $-3.11 | $4.86 | $4.16 | $4.90 | $1.41 | $3.50 | $3.90 |
| EPS (Diluted) | $0.03 | $-4.83 | $-1.23 | $-3.11 | $4.74 | $4.02 | $4.69 | $1.33 | $3.29 | $3.66 |
| Weighted Avg Shares (Basic) | 24.6M | 24.4M | 24.1M | 23.9M | 21.2M | 20.9M | 20.6M | 20.4M | 19.6M | 16.2M |
| Weighted Avg Shares (Diluted) | 24.9M | 24.4M | 24.1M | 23.9M | 21.8M | 21.6M | 21.5M | 21.6M | 20.9M | 17.3M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $9M buybacks = $9M returned on $92M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: 0%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
$64M of principal comes due within a year. Scheduled principal only (excludes interest & revolver draws). As of 2024-09-30 (10-Q).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~7.3% on $1.3B of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 52th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 59.3 | 62.7 | 63.7 | 62.7 | 69.4 | 67.2 | 65.4 | 63.2 |
| Gross Profit | 40.7 | 37.3 | 36.3 | 37.3 | 30.6 | 32.8 | 34.6 | 36.8 |
| R&D | 3.8 | 3.8 | 3.4 | 3.6 | 4.1 | 3.8 | 3.7 | 3.9 |
| SG&A | 22.9 | 21.9 | 22.3 | 23.0 | 26.7 | 26.9 | 26.8 | 28.0 |
| Operating Income | 2.1 | 8.5 | 7.7 | 9.4 | -1.9 | 1.0 | 1.8 | 1.9 |
| Income Tax | -0.5 | 1.1 | 0.8 | 1.5 | -1.8 | -2.2 | 2.2 | 0.1 |
| Net Income | 2.1 | 8.0 | 6.8 | 7.8 | -3.3 | -1.3 | -4.9 | 0.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ICUI: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| ICUI | $3.8B | 5187.3× | 21.1× | 1.7× | -6.3% | 36.8% | 0.0% | 0.0% | 0.0% | 5.3× | 262 |
Peers = companies sharing ICUI's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.